Extended Data Fig. 7: Exploratory analysis of the use 89Zr-atezolizumab-PET to evaluate PD-L1 distribution in ILC patients. | Nature Cancer

Extended Data Fig. 7: Exploratory analysis of the use 89Zr-atezolizumab-PET to evaluate PD-L1 distribution in ILC patients.

From: PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

Extended Data Fig. 7

Representative images of one patient imaged with FDG-PET and 89Zr-atezolizumab-PET. Left panel represents lateral view of baseline FDG-PET, the middle panel represents the lateral view of baseline 89Zr-atezolizumab-PET and the right panel 89Zr-atezolizumab-PET after two cycles of carboplatin.

Back to article page